Trial Profile
A cross-sectional study comparing the efficacy of raltegravir based anti-HIV regimen against non-nucleoside reverse transcriptase inhibitor or protease inhibitor based regimens in adults with HIV-1 infections
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 31 Dec 2015
Price :
$35
*
At a glance
- Drugs Raltegravir (Primary) ; Atazanavir; Darunavir; Efavirenz; Lopinavir; Nevirapine; Rilpivirine
- Indications HIV-1 infections
- Focus Pharmacodynamics
- 31 Dec 2015 New trial record